For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, July 15, 2025 (HealthDay News) — In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.<\/p>\n
Dima Bechenati, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined whether tirzepatide efficacy differs between postmenopausal women using MHT (+MHT) versus those not using MHT (\u2212MHT) in the treatment of overweight and obesity. Propensity score matching was used in a real-world study, with each +MHT participant matched to two \u2212MHT controls based on age, body mass index, age at menopause, menopause type, and diabetes status.<\/p>\n
A total of 120 women were included in the analysis after propensity score matching: 40 in the +MHT group and 80 in the \u2212MHT group. The median follow-up duration was 18 months for both groups. The researchers found that at the last follow-up, significantly greater total body weight loss was achieved by the +MHT versus the \u2212MHT group (17 versus 14 percent). In addition, the proportion of women who achieved \u226520 percent total body weight loss by the last follow-up was higher in the +MHT versus the \u2212MHT group (45 versus 18 percent).<\/p>\n
“These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” coauthor Regina Castaneda, M.D., also from the Mayo Clinic, said in a statement.<\/p>\n